Emiplacel

Unassigned

New Medicines

Critical limb ischaemia with minor tissue loss for patients with peripheral arterial disease or muscle injuries who are unsuitable for revascularisation

Information

Advanced therapy medicinal product (ATMP)
Pluristem Therapeutics
Pluristem Therapeutics

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

PLX PAD is a human placental stromal cell therapy. Mesenchymal stromal cells prevent allostimulation in vivo and control checkpoints of Th1 priming: migration of human dendritic cells to lymph nodes and NK cell activation
Approximately 20% of people aged over 60 years have some degree of peripheral arterial disease, with greater prevalence in people with cardiovascular disease and risk factors such as diabetes, smoking and dyslipidaemia. Critical limb ischaemia occurs in around 1% of all people with peripheral arterial disease, with an estimated annual incidence of between 50 and 1,000 new cases per million population [3].
Critical limb ischaemia with minor tissue loss for patients with peripheral arterial disease or muscle injuries who are unsuitable for revascularisation
Intramuscular

Trial or other data

Dec 19 · No UK trial sites [10]

Evidence based evaluations

1st January 2018 · NIHR